Pcsa stock.

PROCESSA PHARMACEUTICALS INC (PCSA) US74275C3043 - Common Stock . 1.58 +0.02 (+1.28%) After market: 1.45 -0.13 (-8.23%) Profile . Stock Chart . Technical Analysis . Fundamental Analysis . Analyst Ratings . Estimates . Financials . Ownership . News . Full profile views are only available for registered users, you can see which data is available …Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces CEO George Ng's corporate overview presentation at the Biotech Showcase 2024, focusing on developing next-gen chemotherapeutic drugs for cancer patients.Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces positive outcomes from a meeting with the FDA regarding the next Phase 2 study for Next Generation Capecitabine ('NGC-Cap') for cancer patients. The FDA provided helpful guidance on the study design and dosage regimen, based on positive interim results …Processa Pharmaceuticals (NASDAQ:PCSA) on Friday priced the public offering of its stock and warrants to raise gross proceeds of up to $7 million.The offering will consist of 1,555,555 shares or ...The Company’s common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Monday, January 22, 2024. Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304.

The pharmaceutical company revealed plans to offer 1,555,555 shares of its common stock, along with common warrants enabling the purchase of 1,555,555 units of common stock. The offering involves both the common stock and its accompanying warrants at a bundled price of $4.50 each. Dyadic International Inc. (NASDAQ: DYAI) …

$2.1100. Previous Close- YTD Change. -68.77% 12 Month Change. -82.64% Day Range2.0800 - 2.1900.

PCSA Stock Price. -82.28% May 2024 Mar 2024 Jan 2024 Nov 2023 Sep 2023 Jul 2023 0 5 10 15 20. 52 Week Range. 1.40 18.00. Day Range. 2.08 2.19. EPS (FWD) -3.82. PE. - …PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ...You can find your newly purchased PCSA stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. Processa Pharmaceuticals Stock Earnings The value each PCSA share was expected to gain vs. the value that each PCSA share actually gained.With Processa Pharmaceuticals stock trading at $2.22 per share, the total value of Processa Pharmaceuticals stock (market capitalization) is $6.34M. Processa Pharmaceuticals stock was originally listed at a price of $2,058.00 in Nov 21, 2013. If you had invested in Processa Pharmaceuticals stock at $2,058.00, your return over the last …PCSA. 2.090. -1.88%. Webull offers Processa Pharmaceuticals Inc (PCSA) historical stock prices, in-depth market analysis, NASDAQ: PCSA real-time stock quote data, in-depth charts.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for cancer patients. CEO George Ng recently issued a letter to shareholders, emphasizing the company's pivot to focus on oncology drug …

May 6, 2024 · Rhea-AI Summary. Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has closed a public offering of 1,555,555 shares of common stock and common warrants, raising $7.0 million in gross proceeds. The offering price per share was $4.50, with the common warrants having an exercise price of $4.50 per share and a term of five years.

View today's Processa Pharmaceuticals Inc stock price and latest PCSA news and analysis. Create real-time notifications to follow any changes in the live stock price. A high-level overview of Processa Pharmaceuticals, Inc. (PCSA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ...PCSA is unchanged $0.00 from the previous closing price of $0.55 on volume of 537,604 shares. Over the past year the S&P 500 has risen 17.03% while PCSA is lower by -70.59%. PCSA lost -$1.44 per share the over the last 12 months. Click Here to get the full Stock Report for Processa Pharmaceuticals Inc stock.Jan 26, 2024 ... The market value of their outstanding shares is at $4.9 million. Processa Pharma (NASDAQ:PCSA) stock declined by 28.63% to $3.64. The ... Find the latest news headlines from Processa Pharmaceuticals, Inc. Common Stock (PCSA) at Nasdaq.com. Find the latest Processa Pharmaceuticals, Inc. (PCSA) stock quote, history, news and other vital information to help you with your stock trading and investing.

May 10, 2024 · About MetroPCS Communications Stock (NYSE:PCS) T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA. 3 days ago · T-Mobile US, Inc. specializes in mobile telecommunication services. Sales break down by activity as follows: - mobile telecommunication services (80.5%): mobile telephone service, long-distance telephone service, data transmission, Internet access, directory services, etc. serving 119.7 million subscribers at the end of 2023; - equipment sales (18%): primarily handsets and accessories; - other ... Find the latest Processa Pharmaceuticals, Inc. (PCSA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will ex...Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) successfully completed the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (NGC-Cap), a cancer treatment metabolite. NGC-Cap provides 2-10 times greater exposure to its 5-FU metabolite than capecitabine administration, with better tolerance and positive …The PCSA shares have gain 17.97% over the last week, with a monthly amount glided 20.26%, and seem to be Processa Pharmaceuticals Inc [PCSA] stock prices are up 20.26% to $2.79 at the moment. It is a good measure of the stock's recent performance to check whether the stock's short-term value is rising or falling.

Processa Pharmaceuticals Inc. is a development-stage pharmaceutical company that uses a unique approach to develop not discover drugs that help in the treatment of oncology …PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ...

According to 3 analysts, the average rating for PCSA stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 170.27% from the latest price. PCSA Signals & Forecast. The Processa Pharmaceuticals Inc. stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.PCSA Stock Data Market Cap 7.09M. Float 2.49M. Insiders Ownership 11.27%. Institutions Ownership 1.98%. Short Percent 1.25%. Industry Heavy Duty Truck Manufacturing. Sector Manufacturing. Website Link. Country United States of America. City HANOVER. About PCSA. processa pharmaceuticals was founded in october 2017 with …5.8400. 5.2000. 5.2400. 5.2400. 2,125. *Close price adjusted for splits. **Close price adjusted for splits and dividend and/or capital gain distributions. Discover historical prices for PCSA stock on Yahoo Finance. View daily, weekly or monthly formats back to when Processa Pharmaceuticals, Inc. stock was issued.The current Processa Pharmaceuticals [ PCSA] share price is $2.35. The Score for PCSA is 30, which is 40% below its historic median score of 50, and infers higher risk than normal. PCSA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.4 days ago ... PCSA Stock Earnings: Processa Pharma Reported Results for Q1 2024 · Processa Pharma reported earnings per share of -$1.11. · The company did not ....Processa (PCSA) stock rallied 25% after the company said it plans to expand development of NGC-Cap into breast cancer to provide a more efficient pathway to potential FDA approval.Processa Pharmaceuticals, Inc. announces plans to expand the development of NGC-Cap into the treatment of advanced or metastatic breast cancer. The FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design, making the development a more efficient and straightforward path to approval. The expansion into breast cancer represents a larger market than ...

PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ...

Sprint Nextel Merger - August 12, 2005. On August 12, 2005, the merger between Sprint Corporation (NYSE: FON) and Nextel Communications Inc. (NASDAQ: NXTL) was completed and Sprint Corporation changed its name to Sprint Nextel Corporation. Sprint Nextel common stock began trading on the New York Stock Exchange Monday, August 15, 2005, under the ...

4 days ago ... PCSA Stock Earnings: Processa Pharma Reported Results for Q1 2024 · Processa Pharma reported earnings per share of -$1.11. · The company did not ....The current Processa Pharmaceuticals [ PCSA] share price is $2.35. The Score for PCSA is 30, which is 40% below its historic median score of 50, and infers higher risk than normal. PCSA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.Discover historical prices for PCSA stock on Yahoo Finance. View daily, weekly or monthly format back to when Processa Pharmaceuticals, Inc. stock was issued.PCSA is unchanged $0.00 from the previous closing price of $0.55 on volume of 537,604 shares. Over the past year the S&P 500 has risen 17.03% while PCSA is lower by -70.59%. PCSA lost -$1.44 per share the over the last 12 months. Click Here to get the full Stock Report for Processa Pharmaceuticals Inc stock.May 10, 2024 · Price vs Fair Value. View History. PCSA is trading within a range we consider fairly valued. Price. $2.06. May 10, 2024. Fair Value. $3.41. May 10, 2024. PCSA's current price target is $8.00. Learn why top analysts are making this stock forecast for Processa Pharmaceuticals at MarketBeat.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past...Price vs Fair Value. View History. PCSA is trading within a range we consider fairly valued. Price. $2.06. May 10, 2024. Fair Value. $3.41. May 10, 2024.About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Processa Pharmaceuticals, Inc. Common Stock (PCSA) Pre ...Processa Pharmaceuticals, Inc. (PCSA) Add to watchlist. NasdaqCM - NasdaqCM Delayed Price. Currency in USD. 2.2200 +0.1300 (+6.22%) At close: 04:00PM EDT. 2.1600 -0.06 …

3.1900. 3.2900. 3.2900. 23,200. *Close price adjusted for splits. **Close price adjusted for splits and dividend and/or capital gain distributions. Discover historical prices for PCSA stock on Yahoo Finance. View daily, weekly or monthly formats back to when Processa Pharmaceuticals, Inc. stock was issued.Processa Pharmaceuticals Inc (PCSA) stock has risen 4.99% while the S&P 500 is lower by -0.08% as of 9:46 AM on Monday, Mar 4. PCSA has risen $0.12 from the previous closing price of $2.46 on volume of 7,228 shares. Over the past year the S&P 500 is up 26.79% while PCSA is lower by -80.15%. PCSA lost -$22.82 per share in the over the last 12 ...Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has announced a public offering of 1,555,555 shares of common stock and common warrants, with a combined public offering price of $4.50 per share. The gross proceeds from the offering are expected to be $7.0 million. The common warrants will have an exercise price of $4.50 per share and a term of five years after their original issuance date.Instagram:https://instagram. it movie 2bank of baroda bookcosby creek cabinssoulmate moon phase test Processa Pharmaceuticals (PCSA) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals, with a price …The consensus among . 1 Wall Street analyst covering (NASDAQ: PCSA) stock is to Buy PCSA stock.Out of . 1 analyst, 0 (0%) are recommending PCSA as a Strong Buy, 1 (100%) are recommending PCSA as a Buy, 0 (0%) are recommending PCSA as a Hold, 0 (0%) are recommending PCSA as a Sell, and 0 (0%) are recommending PCSA as a Strong Sell.If … harry and snowmanriverbanks zoo garden Processa Pharmaceuticals Price Performance. PCSA opened at $2.18 on Monday. The firm has a market capitalization of $6.23 million, a PE ratio of -0.44 and a … translate chinese Processa Pharmaceuticals Inc. is a development-stage pharmaceutical company that uses a unique approach to develop not discover drugs that help in the treatment of oncology and other high unmet medical need diseases with unparalleled regulatory science and clinical expertise. Our drug candidates are intended for patients who have limited ... If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up t...